Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hyperlipoproteinemias
  Free Subscription

Articles published in
Atherosclerosis
    September 2025
  1. YANG X, Alexander VJ, Xia S, Tsimikas S, et al
    Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndrome.
    Atherosclerosis. 2025;408:120462.
    >> Share

  2. MIJNSTER RJM, Mulder JWCM, Galema-Boers AMH, Mattace-Raso F, et al
    Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry.
    Atherosclerosis. 2025;408:120229.
    >> Share

    July 2025
  3. CASTRO CABEZAS M, Klop B
    The "SMART" side of hypertriglyceridemia.
    Atherosclerosis. 2025 Jul 25:120467. doi: 10.1016/j.atherosclerosis.2025.120467.
    >> Share

  4. TOFT-NIELSEN F, Emanuelsson F, Nordestgaard BG, Benn M, et al
    Clinical familial hypercholesterolemia, heart healthy dietary adherence, and cardiovascular risk.
    Atherosclerosis. 2025 Jul 24:120463. doi: 10.1016/j.atherosclerosis.2025.120463.
    >> Share

  5. KAYIKCIOGLU M
    Making the invisible visible: Leveraging electronic health records to uncover familial hypercholesterolemia in primary care.
    Atherosclerosis. 2025 Jul 22:120454. doi: 10.1016/j.atherosclerosis.2025.120454.
    >> Share

  6. WANG H, Shen C, Yang Y, Li X, et al
    Pigment epithelium-derived factor prevents endothelial dysfunction in early stage of hyperlipidemia by regulating endothelial fatty acid transport.
    Atherosclerosis. 2025;408:120446.
    >> Share

  7. SVENDSEN K, Christensen JJ, Igland J, Krogh HW, et al
    Risk of adverse pregnancy outcomes and impact of statin use in pregnant women with familial hypercholesterolemia.
    Atherosclerosis. 2025;408:120442.
    >> Share

  8. AKYEA RK, Qureshi N
    Uncovering familial hypercholesterolaemia phenotype in the community: How primary care can transform early detection and management.
    Atherosclerosis. 2025 Jul 9:120427. doi: 10.1016/j.atherosclerosis.2025.120427.
    >> Share

  9. TADA H, Furukawa A, Kojima N, Usui S, et al
    Protein-truncating variants of the cholesteryl ester transfer protein gene and risk for coronary artery disease among patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2025;408:120417.
    >> Share

    June 2025
  10. SHAO C, Zhang S, Cheng Z, Yang K, et al
    Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.
    Atherosclerosis. 2025;407:120408.
    >> Share

  11. SCHUITEMA PCE, Visseren FLJ, Nordestgaard BG, Teraa M, et al
    Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease.
    Atherosclerosis. 2025 Jun 14:120411. doi: 10.1016/j.atherosclerosis.2025.120411.
    >> Share

  12. GIJON-CONDE T, Banegas JR, Sanchez CF, Alonso R, et al
    Clinical profile of familial hypercholesterolemia phenotype in adults attended in primary care in a large healthcare area.
    Atherosclerosis. 2025 Jun 4:120400. doi: 10.1016/j.atherosclerosis.2025.120400.
    >> Share

    May 2025
  13. NIGMANN C, Neyer M, Draxler-Dworzak S, Baumgartner-Kaut M, et al
    Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C.
    Atherosclerosis. 2025;406:119234.
    >> Share

  14. KHOLAIF N, Batha L, Aljenedil S, Awan ZA, et al
    Homozygous familial hypercholesterolemia evaluation and survival single center study in Saudi Arabia: The HESSA registry.
    Atherosclerosis. 2025;405:119214.
    >> Share

  15. VAHDAT-LASEMI F, Farhoudi L, Hosseinikhah SM, Santos RD, et al
    Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia.
    Atherosclerosis. 2025;405:119235.
    >> Share

    April 2025
  16. SANTOS RD, Ray KK, De Bacquer D, Jennings C, et al
    Frequency of residual combined dyslipidemia and hypertriglyceridemia in patients with coronary heart disease in 13 countries across 6 WHO Regions: Results from INTERASPIRE.
    Atherosclerosis. 2025;405:119215.
    >> Share

  17. BASHIR B, Pasha R, Kamath A, Malik RA, et al
    Small nerve fibre damage and cardiac autonomic dysfunction in patients with hypertriglyceridaemia.
    Atherosclerosis. 2025;405:119186.
    >> Share

  18. TADA H, Nohara A, Usui S, Sakata K, et al
    Impact of the clinical diagnostic strata of familial hypercholesterolemia on risk stratification among patients with hypercholesterolemia.
    Atherosclerosis. 2025;404:119185.
    >> Share

  19. MULDER JWCM, Schonck WAM, Tromp TR, Reijman MD, et al
    Real-world family planning and pregnancy practices in women with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2025;404:119187.
    >> Share

  20. BRINTON EA, Eckel RH, Gaudet D, Ballantyne CM, et al
    Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA.
    Atherosclerosis. 2025;403:119114.
    >> Share

    March 2025
  21. STONEHOUSE W, Benassi-Evans B, Louise J
    The effects of a novel nutraceutical combination on low-density lipoprotein cholesterol and other markers of cardiometabolic health in adults with hypercholesterolaemia: A randomised double-blind placebo-controlled trial.
    Atherosclerosis. 2025;403:119177.
    >> Share

  22. MICHIKURA M, Ogura M, Hori M, Matsuki K, et al
    Association of Achilles tendon thickness with lipid profile and carotid IMT in patients with familial hypercholesterolemia.
    Atherosclerosis. 2025;403:119173.
    >> Share

  23. VAN DEN BOSCH SE, Hutten BA, Revers A, Schrauben EM, et al
    Association between statin adherence and arterial stiffness in young adult patients with familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2025;404:119175.
    >> Share

    February 2025
  24. DANIELE T, Laura D, Miriam L, Diane B, et al
    The vicious circle of chronic kidney disease and hypertriglyceridemia: What is first, the hen or the egg?
    Atherosclerosis. 2025;403:119146.
    >> Share

  25. IYEN B, Qureshi N, Kai J, Capps N, et al
    Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): A retrospective cohort study of individuals with FH in UK primary care and the UK Simon Broome register, linked with national
    Atherosclerosis. 2025;403:119142.
    >> Share

  26. AIN Q, Sikonja J, Sadiq F, Shafi S, et al
    Cascade screening of a Pakistani consanguineous familial hypercholesterolemia cohort: Identification of seven new homozygous patients.
    Atherosclerosis. 2025;402:119118.
    >> Share

  27. PAVANELLO C, Suppressa P, Castiglione S, Di Costanzo A, et al
    Sex-related differences in response to lomitapide in HoFH: A subanalysis of the Pan-European Lomitapide retrospective observational study.
    Atherosclerosis. 2025;401:119089.
    >> Share

    January 2025
  28. LIN J, Ji Y, Wang G, Ma X, et al
    Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial.
    Atherosclerosis. 2025;403:119120.
    >> Share

  29. GROSELJ U, Kafol J, Molk N, Sedej K, et al
    Prevalence, genetic variants, and clinical implications of hypocholesterolemia in children.
    Atherosclerosis. 2025;400:119065.
    >> Share

    December 2024
  30. AZAR Y, Ludwig TE, Le Bon H, Strom TB, et al
    The singular French PCSK9-p.Ser127Arg gain-of-function variant: A significant player in cholesterol levels from a 775-year-old common ancestor.
    Atherosclerosis. 2024;399:118596.
    >> Share

  31. HEATON J, Alshami A, Imburgio S, Upadhyaya V, et al
    Comparison of pooled cohort equation and PREVENT risk calculator for statin treatment allocation.
    Atherosclerosis. 2024;399:118626.
    >> Share

    November 2024
  32. SCHETTLER VJJ, Selke N, Jenke S, Zimmermann T, et al
    The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.
    Atherosclerosis. 2024;398:118601.
    >> Share

    October 2024
  33. BENITEZ-AMARO A, Garcia E, La Chica Lhoest MT, Martinez A, et al
    Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization.
    Atherosclerosis. 2024 Oct 19:118630. doi: 10.1016/j.atherosclerosis.2024.118630.
    >> Share

  34. SMITH TKT, Ghorbani P, LeBlond ND, Nunes JRC, et al
    AMPK-mediated regulation of endogenous cholesterol synthesis does not affect atherosclerosis in a murine Pcsk9-AAV model.
    Atherosclerosis. 2024;397:117608.
    >> Share

    September 2024
  35. LLEWELLYN A, Simmonds M, Marshall D, Harden M, et al
    Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials.
    Atherosclerosis. 2024 Sep 28:118598. doi: 10.1016/j.atherosclerosis.2024.118598.
    >> Share

  36. BEA AM, Gonzalez-Guerrero A, Cenarro A, Lamiquiz-Moneo I, et al
    Association of HDL cholesterol with all-cause and cardiovascular mortality in primary hypercholesterolemia.
    Atherosclerosis. 2024 Sep 26:118617. doi: 10.1016/j.atherosclerosis.2024.118617.
    >> Share

    August 2024
  37. STOYELL-CONTI FF, Suresh Kumar M, Zigmond ZM, Rojas MG, et al
    Gene inactivation of lysyl oxidase in smooth muscle cells reduces atherosclerosis burden and plaque calcification in hyperlipidemic mice.
    Atherosclerosis. 2024;397:118582.
    >> Share

  38. EYRICH TM, Dalila N, Christoffersen M, Tybjaerg-Hansen A, et al
    Polygenic risk of high LDL cholesterol and ischemic heart disease in the general population.
    Atherosclerosis. 2024;397:118574.
    >> Share

    June 2024
  39. TADA H, Takamura M
    Toward personalized medicine in patients with familial hypercholesterolemia.
    Atherosclerosis. 2024 Jun 18:118522. doi: 10.1016/j.atherosclerosis.2024.118522.
    >> Share

  40. IBRAHIM S, Hartgers ML, Reeskamp LF, Zuurbier L, et al
    LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia.
    Atherosclerosis. 2024 Jun 10:117610. doi: 10.1016/j.atherosclerosis.2024.117610.
    >> Share

    May 2024
  41. BERBERICH AJ, Hegele RA
    Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome.
    Atherosclerosis. 2024;392:117528.
    >> Share

    April 2024
  42. HARADA-SHIBA M
    How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?
    Atherosclerosis. 2024 Apr 16:117551. doi: 10.1016/j.atherosclerosis.2024.117551.
    >> Share

  43. HENDY LE, Spees LP, Tak C, Carpenter DM, et al
    An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
    Atherosclerosis. 2024;393:117541.
    >> Share

  44. IBRAHIM S, Nurmohamed NS, Nierman MC, de Goeij JN, et al
    Enhanced identification of familial hypercholesterolemia using central laboratory algorithms.
    Atherosclerosis. 2024;393:117548.
    >> Share

  45. BASHIR B, Kwok S, Wierzbicki AS, Jones A, et al
    Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
    Atherosclerosis. 2024;391:117476.
    >> Share

    March 2024
  46. REIJMAN MD, Kusters DM, Groothoff JW, Arbeiter K, et al
    Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.
    Atherosclerosis. 2024;392:117525.
    >> Share

  47. ALONSO R, Arroyo-Olivares R, Diaz-Diaz JL, Fuentes-Jimenez F, et al
    Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Atherosclerosis. 2024 Mar 16:117516. doi: 10.1016/j.atherosclerosis.2024.117516.
    >> Share

  48. MELNES T, Bogsrud MP, Christensen JJ, Rundblad A, et al
    Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease.
    Atherosclerosis. 2024;392:117507.
    >> Share

  49. ESCATE R, Padro T, Perez de Isla L, Fuentes F, et al
    Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients.
    Atherosclerosis. 2024;392:117502.
    >> Share

  50. SCHLEGEL A
    Diagnostic challenge of an APOB variant of uncertain significance resolved by transheterozygosity with a pathological LDLR variant and clinical response to therapy.
    Atherosclerosis. 2024;390:117460.
    >> Share

    February 2024
  51. GUAY SP, Paquette M, Taschereau A, Girard L, et al
    Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia.
    Atherosclerosis. 2024 Feb 27:117489. doi: 10.1016/j.atherosclerosis.2024.117489.
    >> Share

    January 2024
  52. RAGGI P, Takyar FM, Gadiyaram V, Zhang C, et al
    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial.
    Atherosclerosis. 2024;388:117425.
    >> Share

    December 2023
  53. WODAJE T, Mahdi A, Venkateshvaran A, Habel H, et al
    Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2023;389:117439.
    >> Share

  54. ANDRADE MM, Neto Goncalves T, Cruz D
    Familial hypercholesterolemia diagnostic challenge: Is Artificial Intelligence the key?
    Atherosclerosis. 2023 Dec 27:117435. doi: 10.1016/j.atherosclerosis.2023.117435.
    >> Share

  55. FISHBEIN I, Inamdar VV, Alferiev IS, Bratinov G, et al
    Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.
    Atherosclerosis. 2023;390:117432.
    >> Share

    November 2023
  56. MOLOKHIA M, Wierzbicki AS, Williams H, Kirubakaran A, et al
    Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London.
    Atherosclerosis. 2023;388:117353.
    >> Share

  57. ZUBIRAN R, Vargas-Vazquez A, Olvera FDR, Cruz-Bautista I, et al
    Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia.
    Atherosclerosis. 2023;386:117364.
    >> Share

  58. HOLVEN KB, Roeters van Lennep J
    Sex differences in lipids: A life course approach.
    Atherosclerosis. 2023;384:117270.
    >> Share

  59. GOLDBERG AC, Banach M, Catapano AL, Duell PB, et al
    Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Atherosclerosis. 2023;384:117192.
    >> Share

    October 2023
  60. KATZMANN JL, Laufs U
    Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?
    Atherosclerosis. 2023 Oct 16:117337. doi: 10.1016/j.atherosclerosis.2023.117337.
    >> Share

  61. JUNNA N, Ruotsalainen S, Ripatti P, FinnGen, et al
    Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease.
    Atherosclerosis. 2023 Oct 12:117327. doi: 10.1016/j.atherosclerosis.2023.117327.
    >> Share

  62. PAGE MM, Hardikar W, Alex G, Bates S, et al
    Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand.
    Atherosclerosis. 2023 Oct 10:117305. doi: 10.1016/j.atherosclerosis.2023.117305.
    >> Share

  63. SANTOS RD
    Improving pediatric familial hypercholesterolemia diagnosis by looking deeper into families.
    Atherosclerosis. 2023 Oct 1:117317. doi: 10.1016/j.atherosclerosis.2023.117317.
    >> Share

    September 2023
  64. ALBUQUERQUE J, Medeiros AM, Alves AC, Jannes CE, et al
    Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults.
    Atherosclerosis. 2023;383:117314.
    >> Share

    August 2023
  65. CASULA M, Gazzotti M, Capra ME, Olmastroni E, et al
    Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
    Atherosclerosis. 2023 Aug 12:117231. doi: 10.1016/j.atherosclerosis.2023.117231.
    >> Share

  66. HON A, Hsu JJ, Zambrano A, Xia Y, et al
    Effects of activity levels on aortic calcification in hyperlipidemic mice as measured by microPETmicroCT.
    Atherosclerosis. 2023;380:117198.
    >> Share

  67. SHAPIRO MD, Taub PR, Louie MJ, Lei L, et al
    Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
    Atherosclerosis. 2023;378:117182.
    >> Share

  68. MURPHY JM, Jeong K, Tran DTK, Cioffi DL, et al
    Nuclear FAK in endothelium: An intrinsic inhibitor of NF-kappaB activation in atherosclerosis.
    Atherosclerosis. 2023;379:117189.
    >> Share

    July 2023
  69. SIMONEN P, Oorni K, Sinisalo J, Strandberg TE, et al
    High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
    Atherosclerosis. 2023;376:53-62.
    >> Share

    June 2023
  70. JONES A, Peers K, Wierzbicki AS, Ramachandran R, et al
    Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Atherosclerosis. 2023;375:67-74.
    >> Share

  71. COSIN-SALES J, Campuzano Ruiz R, Diaz Diaz JL, Escobar Cervantes C, et al
    Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
    Atherosclerosis. 2023;375:38-44.
    >> Share

    May 2023
  72. DOI T, Langsted A, Nordestgaard BG
    Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.
    Atherosclerosis. 2023 May 13:S0021-9150(23)00204.
    >> Share

  73. SONMEZ A, Demirci I, Haymana C, Tasci I, et al
    Clinical characteristics of adult and paediatric patients with familial hypercholesterolemia: A real-life cross-sectional study from the Turkish National Database.
    Atherosclerosis. 2023;375:9-20.
    >> Share

    April 2023
  74. RODRIGUEZ-BORJABAD C, Narveud I, Christensen JJ, Ibarretxe D, et al
    Association between Nordic and Mediterranean diets with lipoprotein phenotype assessed by (1)HNMR in children with familial hypercholesterolemia.
    Atherosclerosis. 2023;373:38-45.
    >> Share

  75. SCHREUDER MM, Hamkour S, Siegers KE, Holven KB, et al
    LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Atherosclerosis. 2023 Apr 13:S0021-9150(23)00139.
    >> Share

  76. HEDEGAARD BS, Bork CS, Kanstrup HL, Thomsen KK, et al
    Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study.
    Atherosclerosis. 2023;373:10-16.
    >> Share

    March 2023
  77. TADA H, Nomura A, Nohara A, Usui S, et al
    Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2023 Mar 17:S0021-9150(23)00103.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016